Equities
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species.

  • Revenue in USD (TTM)47.70bn
  • Net income in USD6.43bn
  • Incorporated1970
  • Employees74.00k
  • Location
    Merck & Co Inc2000 Galloping Hill RdKENILWORTH 07033-1310United StatesUSA
  • Phone+1 (908) 740-4000
  • Fax+1 (908) 423-1987
  • Websitehttp://www.merck.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
MRK:NYQ since
announced
Transaction
value
Acceleron Pharma IncDeal completed30 Sep 202130 Sep 2021Deal completed-0.24%11.59bn
Pandion Therapeutics IncDeal completed25 Feb 202125 Feb 2021Deal completed0.46%1.81bn
Data delayed at least 15 minutes, as of Nov 30 2021 21:10 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Zoetis Inc7.62bn1.98bn105.77bn11.30k53.8422.6243.6213.894.154.1515.959.880.55531.317.04673,982.3014.4312.9916.8115.2469.9767.8725.9822.133.2711.030.584821.886.636.979.2037.0315.1319.23
Amgen, Inc.25.77bn5.61bn114.61bn24.30k20.9613.9912.694.459.719.7144.6014.540.39761.565.821,060,370.008.6511.2010.7013.3675.4280.7021.7733.201.367.390.820644.508.833.25-7.370.91970.46715.16
Bristol-Myers Squibb Co45.47bn-5.41bn121.28bn30.25k--3.2622.222.67-2.40-2.4020.1816.770.38464.646.211,503,074.00-4.562.55-5.543.1979.0072.44-11.845.971.36--0.5455192.9562.6220.75-362.14---1.693.99
Moderna Inc11.83bn7.06bn149.41bn1.30k22.6314.7420.6812.6316.2816.2827.9725.000.9252--7.109,100,573.0055.22--99.86--85.86--59.69--1.25--0.0431--1,234.34---45.34------
Merck & Co., Inc.47.70bn6.43bn189.17bn74.00k29.585.2819.453.972.532.8318.8014.170.52052.545.61644,567.607.037.269.279.4768.7569.5613.5114.951.07--0.424485.462.463.97-29.059.7329.566.62
AbbVie Inc55.17bn7.46bn206.65bn50.00k27.8215.2512.803.754.204.2031.047.660.36975.406.231,173,809.005.057.736.149.7267.8873.8113.6718.070.90647.240.85697.1537.6914.91-41.90-2.408.4518.50
Eli Lilly And Co27.76bn5.97bn243.77bn35.00k38.9331.4332.768.786.556.5530.448.110.60261.875.14793,100.0012.9610.2818.0714.5474.8577.1921.5219.521.02139.260.682356.069.954.2233.5520.794.538.16
Data as of Nov 30 2021. Currency figures normalised to Merck & Co Inc's reporting currency: US Dollar USD

Institutional shareholders

26.45%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 2021199.77m7.89%
BlackRock Fund Advisorsas of 30 Sep 2021126.35m4.99%
SSgA Funds Management, Inc.as of 30 Sep 2021115.54m4.56%
Wellington Management Co. LLPas of 30 Sep 202149.56m1.96%
Geode Capital Management LLCas of 30 Sep 202142.74m1.69%
Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 202131.03m1.23%
Norges Bank Investment Managementas of 31 Dec 202027.52m1.09%
Charles Schwab Investment Management, Inc.as of 30 Sep 202127.50m1.09%
Massachusetts Financial Services Co.as of 30 Sep 202125.50m1.01%
Franklin Advisers, Inc.as of 30 Sep 202124.14m0.95%
More ▼
Data from 31 Dec 2020 - 30 Sep 2021Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.